scispace - formally typeset
M

M. Eric Gershwin

Researcher at University of California, Davis

Publications -  1099
Citations -  57832

M. Eric Gershwin is an academic researcher from University of California, Davis. The author has contributed to research in topics: Primary biliary cirrhosis & Antibody. The author has an hindex of 116, co-authored 1070 publications receiving 51902 citations. Previous affiliations of M. Eric Gershwin include University of Innsbruck & University of California, Berkeley.

Papers
More filters
Journal ArticleDOI

Primary Biliary Cirrhosis

TL;DR: PBC is a chronic cholestatic liver disease characterized by high-titer serum antimitochondrial autoantibodies (AMAs) and autoimmune-mediated destruction of small and medium-sized intrahepatic bile ducts as discussed by the authors.
Journal ArticleDOI

Pathogenesis and natural history of osteonecrosis.

TL;DR: The understanding of the pathogenesis of osteonecrosis is now much better defined and skeletal scintigraphy and magnetic resonance imaging have enhanced diagnosis greatly, helping the physician determine which patients are at risk for oste onecrosis, facilitating early diagnosis and better treatment options.
Journal ArticleDOI

Human autoimmune diseases: a comprehensive update.

TL;DR: The identification of cytokines and chemokines, and their cognate receptors, has led to novel therapies that block pathological inflammatory responses within the target organ and have greatly improved the therapeutic effect in patients with autoimmune disease, particularly rheumatoid arthritis.
Journal ArticleDOI

Risk Factors and Comorbidities in Primary Biliary Cirrhosis: A Controlled Interview-Based Study of 1032 Patients

TL;DR: Environmental factors, possibly including infectious agents through urinary tract infections or chemicals contained in cigarette smoke, may induce PBC in genetically susceptible individuals and exogenous estrogens may also contribute to explain the female predominance of the disease.
Journal ArticleDOI

Probiotics and immunity

TL;DR: Promising results have been obtained with probiotics in the treatment of human inflammatory diseases of the intestine and in the prevention and treatment of atopic eczema in neonates and infants, however, the findings are too variable to allow firm conclusions as to the effectiveness of specific Probiotics in these conditions.